A group of 29 nonprofit organizations filed a letter with the FDA calling on them to foster the development of a robust biosimilars market, which would ultimately reduce prescription drug costs and provide patients with access to more affordable therapies. The letter is available online.
Laboratory Developed Tests (LDTs) have become a source of convenience and hope for patients, but they have also triggered controversy about the safety of their impact on consumer expectations, and about the accuracy of the clinical results they provide. In 2014, the Food and Drug Administration (FDA) and the Centers for Medicare and Medicaid Services […]
For consumers, personal sound amplification devices can boost sound that is too faint for most of us to hear. This technology can be used by consumers who want to temporarily heighten their hearing, including the use of headphones and equipment used to modestly boost the sound on telephones, listening devices and other audio amplification, and […]
Today, ACI joined a broad coalition of nonprofit groups in opposition to a Congressional proposal to give the FDA authority to regulate over-the-counter personal sound application devices sold in many stores, including Best Buy, Walmart and others. These regulations would do little to benefit consumers, but would certainly lead to significantly higher consumer prices. Download the Letter.
When one thinks of counterfeit goods, it can conjure up images of customers being duped into buying inferior quality designer bags or other fashion knockoffs. However, when it comes to the manufacturing, distribution and sale of counterfeit medications, the outcomes can be much more serious and life threatening. Most consumers probably don’t realize that counterfeit […]
Our food supply chain typically delivers an affordable and dizzying smorgasbord of flavor, texture, and variety that satisfies consumers. Food that makes us ill is atypical. Fortunately the Food and Drug Administration (FDA) and the US Department of Agriculture (USDA) are on the job to prevent, or at least minimize, the damage from contaminated or […]
About thirty years ago, generic (unbranded) drugs were first approved by the Federal Drug Administration (FDA) for use by patients. These drugs provided competitive alternatives to more expensive name branded pharmaceuticals, and this competition saved consumers $1.68 trillion (not billion) over the last decade, according to the FDA’s Deputy Commissioner. Lower prices from these alternatives […]
CRISPR is an innovation in genetic engineering expected to accelerate cures and therapies for gene-related problems. Along the way, CRISPR will rekindle ethical controversies. How the US handles these controversies will be key to harvesting the benefits of genetic engineering. CRISPR allows scientists to precisely cut out and replace DNA in genes. It has proven […]
When it comes to drug prices, what’s dominating the headlines is bad news story after bad news story. Turing Pharmaceuticals raised the price of an old AIDS drug by more than 5,000 percent overnight, and Valeant Pharmaceuticals International raised a blood pressure drug price by nearly 3,000 percent since 2013, among other consumer losing examples. […]
The recent approval of the first biosimilar drug by the FDA will mark the beginning of competition for a class of lifesaving medicines in the U.S., after nearly a decade of availability in Europe and elsewhere. This ConsumerGram will explore how the pending introduction of competition for biologic drugs will lead to immense consumer benefits, both […]